Viromed Medical AG (Q11) — Working Capital to Net Assets Ratio
Viromed Medical AG (Q11) has a Working Capital to Net Assets ratio of 12.7% as of September 2025. Working capital of €34.32 Million (current assets of €95.91 Million minus current liabilities of €61.59 Million) is measured against net assets of €269.20 Million. A higher ratio indicates strong short-term liquidity financed by the equity base. See how many days can Viromed Medical AG fund operations to measure how many days the company can operate on defensive assets alone.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Viromed Medical AG Working Capital to Net Assets (2021–2024)
This chart shows how Viromed Medical AG's Working Capital to Net Assets ratio has evolved across 4 annual periods from 2021 to 2024. As of September 2025, the ratio stands at 12.7%, reflecting working capital of €34.32 Million against net assets of €269.20 Million EUR. For the complete balance sheet picture, see Q11 total asset value.
Annual Working Capital to Net Assets for Viromed Medical AG (2021–2024)
The table below presents the year-by-year Working Capital to Net Assets ratio for Viromed Medical AG from 2021 to 2024, covering 4 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. Check Viromed Medical AG (Q11) asset resilience to evaluate the company's liquid asset resilience ratio.
| Year | WC/NA Ratio | Working Capital (EUR) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2024 | 9.4% | €18.90 Million | €201.16 Million | €65.88 Million | €46.97 Million | ▲ +12.0 pp |
| 2023 | -2.6% | €-1.65 Million | €64.28 Million | €40.73 Million | €42.38 Million | ▼ -80.8 pp |
| 2022 | 78.2% | €49.47 Million | €63.23 Million | €50.68 Million | €1.21 Million | ▲ +14.3 pp |
| 2021 | 63.9% | €25.54 Million | €39.97 Million | €27.64 Million | €2.10 Million | — |